CAMBRIDGE, Mass., September 7, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today showcased new data at the Exosome Based Therapeutic Development Summit 5^th Annual Meeting held September 5-7, 2023 in Boston. The presentation highlighted new data on the company’s proprietary ARMM (ARrestin-domain 1 Mediated Microvesicles) delivery technology, including therapeutic in vivo gene editing in a preclinical model of acute liver injury, and summarized biodistribution translation evidence generated across species, including non-human primates.

 

CAMBRIDGE, Mass., May 2, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced eight data presentations at the American Society of Gene & Cell Therapy (ASGCT) 26^th Annual Meeting being held May 16-20, 2023 in Los Angeles. New preclinical data demonstrate efficient delivery of large genome editor and guide RNA complexes, providing further support of the Company’s novel delivery platform.

CAMBRIDGE, Mass., February 7, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally existing vesicles, today announced the expansion of the Scientific Advisory Board with the appointments of Connie Cepko, PhD and Kate Fitzgerald, PhD.

“We are thrilled to welcome Dr. Cepko and Dr. Fitzgerald to our Scientific Advisory Board” said Dr. Joseph Nabhan, Chief Scientific Officer of Vesigen Therapeutics, “At Vesigen, we’re developing therapeutics using a differentiated delivery technology to treat a range of diseases with unmet need. Dr. Cepko brings a wealth of knowledge in retinal diseases and Dr. Fitzgerald adds extensive expertise in innate immune system sensing and signaling. We look forward to their valuable contributions to our drug discovery programs.”

CONNIE CEPKO, PhD

Dr. Cepko is the Bullard Professor of Genetics and Neuroscience at Harvard Medical School in the Department of Genetics and in the Department of Ophthalmology. She co-directs the Leder Human Biology and Translational Medicine Program for PhD students at Harvard University. Her ground-breaking research has advanced understanding of the development of the central nervous system (CNS) and mechanisms of retinal degeneration.

A HHMI Investigator and author of over 230 peer-reviewed publications, Dr. Cepko has earned distinguished honors for her work, ranging from induction to the American Academy of Arts and Sciences in 1999 to receiving a Leading Women Award in 2003, presented by the Patriots’ Trail Girl Scout Council in Boston. Dr. Cepko was also elected to the National Academy of Sciences in 2002.

She trained in virology at Massachusetts Institute of Technology (MIT) with Dr. Phillip Sharp where she earned her PhD and later was a postdoctoral fellow at the MIT Whitehead Institute with Dr. Richard Mulligan, where she created some of the first retroviral vectors. Her laboratory is developing gene therapy to treat retinal degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration.

KATE FITZGERALD, PhD

Dr. Fitzgerald is Professor and Vice Chair of Medicine, Chief of the Division of Innate Immunity, and the Worcester Foundation in Biomedical Sciences Research Chair at the University of Massachusetts Chan Medical School. Her work is focused on the innate immune system aimed at understanding the molecular basis of the inflammatory response during Infection and in autoinflammatory diseases. The long-term goal of her work is to determine how innate immune sensing and signaling contribute to infectious, inflammatory, and autoimmune diseases in humans.

Dr. Fitzgerald completed her education in Ireland. She received her B.Sc. in Biochemistry in 1995 from University College Cork, Ireland and her PhD in Biochemistry in 1999 from Trinity College Dublin, Ireland. After pursing a post-doctoral fellowship at Trinity College Dublin, she joined UMass Chan as Instructor where she has been since 2001. She is currently a tenured Professor of Medicine.

Dr. Fitzgerald is an elected fellow of the American Society of Microbiology and an elected member of the Royal Irish Academy, the National Academy of Sciences (USA) and the National Academy of Medicine (USA). She is the recipient of several awards including the Thermo-Fischer Meritorious Career Award (from the American Association of Immunology), the Saint Patrick’s Day Medal (from the Irish Government and Science Foundation Ireland) and the Milstein Award for Excellence in Interferon and Cytokine research (from the International Cytokine and Interferon Society), amongst others.

She has extensive service both locally at UMass Chan and nationally including service on local and national advisory boards (e.g., Massachusetts Center For Pathogen Readiness, NIAID Board of Scientific Councillors, Burroughs Wellcome Fund Pathogenesis of Infectious Diseases and the Cancer Research Institute). She was also the recent past President of the International Cytokine and Interferon Society.

About Vesigen Therapeutics

Vesigen Therapeutics is a biotechnology company developing novel therapeutics enabled by the engineering of naturally existing vesicles for delivery. Vesigen’s patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads, including gene editing complexes, proteins, and RNAs to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of a range of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet medical needs. ARMMs were discovered and engineered into a drug delivery system at the Harvard T.H. Chan School of Public Health.

For additional information visit www.vesigen.com.

Contact Vesigen:

Vanessa Le
Manager, Business Operations
Email: info@vesigentx.com

CAMBRIDGE, Mass., Apr. 11, 2022 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology, ARMMs, today announced the appointment of Paulash Mohsen as Chief Executive Officer.

“Paulash joins Vesigen with a broad range of skills, experience and accomplishments that are an excellent fit to lead an emerging innovation-focused biotechnology company such as Vesigen,” said Gerald Chan, Sc.D., Chairman of Vesigen’s Board of Directors. “His experience at both large pharma and small biotech companies will be invaluable as we continue advancing our novel programs. On behalf of our Board and management team, we welcome Paulash and look forward to his executive leadership.” Mr. Mohsen is a seasoned biopharmaceutical executive who has served in a variety of roles across multiple disciplines. Prior to his appointment at Vesigen, he served as Chief Business Officer at YumanityTherapeutics, and helped the company grow from a seed stage, research-based startup to a publiccompany, with a lead clinical program in Parkinson’s disease. He was responsible for securing a strategic research collaboration and license agreement with Merck & Co. for two pipeline programs in amyotrophic lateral sclerosis and frontotemporal lobar dementia. Before Yumanity, Mr. Mohsen served as Country Manager in Canada for Cubist Pharmaceuticals (acquired by Merck), where he led the company’s first international operation from conceptualization through commercialization. In this role, he oversaw the approval and launch of two novel anti-infective therapeutics and led the company’s commercial, scientific and administrative functions. Mr. Mohsen joined Cubist via acquisition of Optimer
Pharmaceuticals, where he was Vice President, Strategy and Business Operations and helped establish the U.S. commercial infrastructure and led launch preparedness for DIFICID, an anti-infective. Preceding Optimer, Mr. Mohsen held strategic and operational roles at Pfizer, including Vice President of Strategy and Vice President, Multi-Channel Management. Mr. Mohsen holds a B.S. in Chemical Engineering from
Brown University, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

Vesigen is a biotechnology company developing drugs based on its patented ARRDC1-mediated microvesicles (ARMMs) technology, a class of fusogenic extracellular vesicles produced by cells to package and deliver communication signals between cells and tissues. Currently, a wide range of therapeutic agents, including RNAs, proteins, and gene-editing complexes have been packaged into ARMMs and functionally delivered intracellularly in vitro and in vivo.

“What attracted me to Vesigen was both its innovative platform and the experience and ingenuity of its management team and research staff,” said Mr. Mohsen. “I am excited to begin working with this worldclass team to break through delivery barriers and enable the next generation of therapeutics for patients worldwide.”

About Vesigen Therapeutics

Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), is expanding the universe of druggable targets by enabling the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins
(signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells. The team is committed to leveraging ARMMs technology to develop transformative medicines and address currently unmet medical needs. For additional information visit www.vesigentx.com.

About ARMMs

ARMMs vesicles (ARRDC1-mediated microvesicles) are a class of fusogenic extracellular vesicles produced by cells to package and deliver communication signals between cells and tissues. The ARMMs cellular machinery is partially hijacked by many enveloped viruses, such as HIV and Ebola, to produce viruses which bud out of host cells and have specific targeting properties. ARMMs possess unique
properties not found in other classes of extracellular vesicles (e.g. exosomes), making them better suited for delivering therapeutic agents. It has been demonstrated that a wide range of labile and difficult to deliver therapeutic agents, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) can be packaged into ARMMs and functionally delivered intracellularly in vitro and in vivo. ARMMS vesicles were discovered and engineered into a drug delivery system in the lab of Quan Lu, PhD, Professor of Environmental Genetics and Physiology at the Harvard T.H. Chan School of Public Health with support in particular from Harvard’s Blavatnik Biomedical Accelerator. Vesigen will advance the ARMMs platform to develop innovative medicines for patients through an exclusive license agreement with Harvard University.

Contact Vesigen:

Vanessa Le
Manager, Business Operations
Email: info@vesigentx.com

Vesigen Therapeutics, Inc., a biotechnology company pioneering development of a novel extracellular vesicle-mediated delivery platform, today announced new data supporting the therapeutic potential of ARRDC1 Mediated Microvesicles (ARMMs) as vehicles for intracellular delivery of macromolecules.